Evidence map›Paper›PMID 9836366›Full record

ArticleSpringer seminars in immunopathology1998

Heterogeneity of rheumatoid arthritis: from phenotypes to genotypes.

C M Weyand, P A Klimiuk, J J Goronzy

Abstract read
PubMed Publisher
In one paragraph

Article in Springer seminars in immunopathology, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 1 pooled it
7.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 1 synthesis or guideline pooled it, 130 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Understanding the major risk factors in the beginning and the progression of rheumatoid arthritis: current scenario and future prospects.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2015
    Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

C M WeyandDepartment of Medicine, Mayo Clinic, Rochester, MN 55905, USA.
P A Klimiuk
J J Goronzy
Mayo Clinic · USMayo Clinic in Arizona · USUniversity of Rochester · US

Funding

Oligoclonal T Cell Expansion &Rheumatoid ArthritisR01AR042527 · NIAMS · STANFORD UNIVERSITY · PI WEYAND, CORNELIA M. · 1993 to 2022
$4.8M
DIVERSITY OF T LYMPHOCYTES IN RHEUMATOID ARTHRITISR01AR041974 · NIAMS · MAYO CLINIC COLL OF MEDICINE, ROCHESTER · PI GORONZY, JORG J. · 1994 to 2006
$2.1M
METHOTREXATE EFFECTS IN RHEUMATOID ARTHRITISF05TW005204 · FIC · MAYO CLINIC COLL OF MEDICINE, ROCHESTER · PI KLIMIUK, PIOTR A · 1995 to 1996
–
FIC NIH HHS FO5 TWO5204NIAMS NIH HHS R01 AR41974NIAMS NIH HHS R01 AR42527
6 · The paper itself

Abstract

Rheumatoid arthritis (RA) is now recognized as a multigene disorder with a number of genetic polymorphisms contributing to disease pathogenesis. Here, we propose that the diagnostic category of RA includes multiple subtypes of disease and that the different phenotypes of RA correlate to different genotypes. Support for this concept has come from a reappraisal of the clinical heterogeneity of RA and the observation that HLA-DRB1 polymorphisms are useful in describing genetic heterogeneity of RA phenotypes. A series of HLA-DRB1 genes has been identified as RA associated, and in recent years emphasis has been put on the sequence similarities of these alleles. An alternative view focuses on the amino acid variations found in RA-associated HLA-DRB1 alleles with different alleles being enriched in distinct subtypes of RA. Rheumatoid factor-positive destructive joint disease is predominantly associated with the HLA-DRB1*0401 allele, while HLA-DRB1*0404 and B1*0101 predispose for milder and often seronegative disease. Expression of disease-associated alleles on both haplotypes carries a high risk for extra-articular manifestations. In particular, patients homozygous for HLA-DRB1*0401 frequently develop rheumatoid vasculities on follow-up. Besides HLA gene polymorphisms, abnormalities in the generation and function of CD4 T cells and in inflammatory pathways established in synovial lesions can be used to dissect patient subsets with different variants of RA. Emergence of CD28-deficient CD4 T cells identifies RA patients with extra-articular manifestations. These cells undergo clonal expansion in vivo, produce high amounts of IFN-gamma, and exhibit autoreactivity. Concordance of monozygotic twins for the expression of CD4+ CD28- T cells suggests a role for genetic factors in the generation of these unusual T cells. Evidence for heterogeneity of the synovial component of RA comes from studies describing three distinct patterns of lymphoid organization in the synovium. Based upon the topography of tissue-infiltrating mononuclear cells, diffuse, follicular, and granulomatous variants of rheumatoid synovitis can be distinguished. Each pattern of lymphoid organization correlates with a unique profile of tissue cytokines, demonstrating that several pathways of immune deviation modulate disease expression in RA. A dissection of RA variants would have major implications on how the disease is studied, treated, and managed. Identifying combinations of RA risk genes that correlate with disease variants could, therefore, become an important diagnostic tool.

Indexed as

AllelesArthritis, RheumatoidCD28 AntigensCD4 AntigensCytokinesEpitopes, T-LymphocyteGenetic HeterogeneityGenotypeHLA-DR AntigensHumansPhenotypePolymorphism, GeneticRisk FactorsSynovitisT-LymphocytesT-Lymphocyte SubsetsCD28 AntigensCD4 AntigensCytokinesEpitopes, T-LymphocyteHLA-DR Antigens

Identifiers

PMID9836366
OpenAlexW1978997769

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.